+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dynavax Technologies Corporation - logo

Dynavax is a clinical-stage biopharmaceutical company with multiple product candidates in development for the treatment of autoimmune and inflammatory diseases, and the treatment of cancer. The company’s lead product candidates include HEPLISAV-B, an investigational adult hepatitis B vaccine; and AZD1419, which is in Phase II clinical trial for the treatment of asthma. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.

Immunotherapy Drugs Market - Global Outlook & Forecast 2021-2026 - Product Thumbnail Image

Immunotherapy Drugs Market - Global Outlook & Forecast 2021-2026

  • Report
  • October 2021
  • 210 Pages
  • Global
From
Pertussis - Pipeline Insight, 2024 - Product Thumbnail Image

Pertussis - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 70 Pages
  • Global
From
From
From
From
Rheumatoid Arthritis - Pipeline Review, H2 2020 - Product Thumbnail Image

Rheumatoid Arthritis - Pipeline Review, H2 2020

  • Drug Pipelines
  • July 2020
  • 1191 Pages
  • Global
From
Diphtheria Global Market Report 2024 - Product Thumbnail Image

Diphtheria Global Market Report 2024

  • Report
  • January 2024
  • 175 Pages
  • Global
From
From
Herpes Zoster - Pipeline Insight, 2024 - Product Thumbnail Image

Herpes Zoster - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 85 Pages
  • Global
From
Hepatitis B Vaccines Market 2020-2024 - Product Thumbnail Image

Hepatitis B Vaccines Market 2020-2024

  • Report
  • October 2020
  • 120 Pages
  • Global
From
Pancreatitis - Pipeline Insight, 2024 - Product Thumbnail Image

Pancreatitis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
NK Cell therapies - Pipeline Insight, 2024 - Product Thumbnail Image

NK Cell therapies - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 120 Pages
  • Global
From
Recurrent or Metastatic Head and Neck cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Recurrent or Metastatic Head and Neck cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Loading Indicator